Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities
Executive Summary
U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.
You may also be interested in...
Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices
The federal government will have to take the lead on investigating and potentially punishing past overcharging for drugs as a result of the March 29 ruling.
Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices
The federal government will have to take the lead on investigating and potentially punishing past overcharging for drugs as a result of the March 29 ruling.
Problems With 340B? GAO Is Now Gathering Information From Drug Manufacturers
The Government Accountability Office has begun interviewing pharmaceutical manufacturers about their experiences with the 340B drug discount program in preparation for a report mandated by the Affordable Care Act.